Finally, when evaluated in an in vivo setting, FOXO1 overexpression improved CAR-T cell anti-tumour control in a range of preclinical solid tumour models, including murine breast carcinoma and colon adenocarcinoma, and human ovarian cancer and osteosarcoma. The gene discussed is FOXO1; the disease is neoplasm.